Drug Trial Radar · NCT06764862
Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Jan 17, 2025
Primary completion
Feb 12, 2026
Study completion Mar 4, 2026
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
HSK44459 dose 1Drug
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 dose 2Drug
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 dose 3Drug
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
PlaceboDrug
Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change from baseline in forced vital capacity (FVC) at week 12Time frame: day 1 and week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.